Table 2.
Summary of literature related to second-line chemotherapy and targeted therapies for metastatic bladder cancer.
| Chemotherapy | Targeted Therapies | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Bellmunt et al. [14] | Bellmunt et al. [14] | Joly et al. [15] | Fechner et al. 2006 [16] | Fechner et al. 2006 [16] | Sweeney et al. [17] | Hussain et al. [18] | Wulfing et al. [19] | Hahn et al. [20] | Rosenberg et al. [21] | Gomez-Abuin et al. [22] | |
| Chemotherapy regime | Vinflunine + Best supportive care | Best supportive care alone | Paclitaxel | Gem-Pac 3 weekly regime | Gem-Pac 2 weekly regime | Pemetrexed | Trastuzumab plus Pac, Carbo, and Gem | Lapatinib | GC + Bevacizumab | Bortezomib | Bortezomib |
| Response Rate (%) | 8.6 | 0 | 9 | 50 | 38 | 27.7 | 70 | 3 | 67 | 0 | 0 |
| Complete Response rate (%) | 0 | 0 | 2 | 50 | 7 | 6.4 | 11.4 | 0 | 17 | 0 | 0 |
| Median time to progressive disease (months) | 3 | 11 | 6 | 9.3 | 2 | 1.4 | 1.9 | ||||
| Median survival (months) | 6.9 | 4.3 | 7 | 13 | 9 | 9.6 | 14 | 4.1 | 19.1 | 5.7 | 3.5 |
| Toxicity | |||||||||||
| Grade 3 or 4 Neutropenia (%) |
50 | 2.7 | 36 | 23 | 4.3 | 86.4 | 35 | 0 | 0 | ||
| Neutropenic sepsis or febrile neutropenia (%) | 6 | 0 | 4 | 40.9 | 2 | 0 | 0 | ||||
| Drug-related deaths (%) |
5 | 1.7 | 7 | 0 | 0 | ||||||